NOV

9.09%

7.0¢ novatti group limited

Ann: Annual Report to shareholders, page-19

First 19 Last

Gorix

337 Posts.

02/10/23

16:59

Post #: 70133867

Originally posted by Anton: ↑
With the NOV share price currently on life support I thought I would cheer myself up .. Enjoy your long weekend.
From the recent Annual Report .... Consolidated Sales Revenue (only) Appears to be heading in the right direction ..
Expenses - I guess we will get an indication of 24Q1 actuals before the end of October.
Sales revenue $ $ $ 2022 2023 2022 to 2023 2024 Projected
1
x $1000 x $1000 % change x $1000
2

assume same %
3 Technology $3,876.00 $4,406.00 13.67% $5,008.47
4 Business Automation $2,439.00 $2,148.00 -11.93% $1,891.72
5 Acquiring $868.00 $2,591.00 198.50% $7,734.19
6 Alternative Payments $17,946.00 $20,847.00 16.17% $24,216.95
7 Banking Services - - - $- $-
$-
8 ATX Payments $5,801.00 $5,564.00 -4.09% $5,336.68
9 Issuing $1,625.00 $3,423.00 110.65% $7,210.42
10

$-
11
$32,555.00 $38,979.00 19.73% $46,670.63
Cheers Anton
Expand
Doesn’t matter how much revenue they keep growing if the cash flow is negative every quarter.
The only slightly cheery place to be is an executive in No receiving free options with appropriately reducing strike prices.

NOV Price at posting: 9.4¢ Sentiment: None Disclosure: Held

4 Upvote

0 Great analysis

Top Stories

COD

Coda Minerals (ASX:COD) enters rights issue to further exploration in South Australia

OJC

SPC to merge with Original Juice Co and Nature One Dairy

RCE

Recce eyes Indonesia for novel anti-infective as Indo-Aus ties grow stronger

COB

Cobalt Blue sees A$60M price tag for Kwinana, WA refinery – but $68M value for stage one

ACW

Actinogen Medical ramps up Alzheimer’s treatment trials, targeting fast-track global approvals

There are more pages in this discussion • 7 more messages in this thread...

First 19 Last

Add NOV (ASX) to my watchlist

(20min delay)
Last 7.0¢		Change -0.007(9.09%)		Mkt cap ! $24.90M

Open	High	Low	Value	Volume
7.7¢	7.7¢	7.0¢	$30.20K	417.5K

Buyers (Bids)

No.	Vol.	Price($)
2	21700	6.7¢

Sellers (Offers)

Price($)	Vol.	No.
7.2¢	171713	2

View Market Depth

No.	Vol.	Price($)
2	21700	0.067
1	105000	0.066
6	224134	0.065
1	47619	0.063
1	70000	0.062

Price($)	Vol.	No.
0.072	171713	2
0.074	12000	1
0.079	38710	1
0.080	220000	2
0.083	29999	1

Last trade - 15.57pm 02/10/2024 (20 minute delay)

NOV (ASX) Chart

Ann: Annual Report to shareholders, page-19

Coda Minerals (ASX:COD) enters rights issue to further exploration in South Australia

SPC to merge with Original Juice Co and Nature One Dairy

Recce eyes Indonesia for novel anti-infective as Indo-Aus ties grow stronger

Cobalt Blue sees A$60M price tag for Kwinana, WA refinery – but $68M value for stage one

Actinogen Medical ramps up Alzheimer’s treatment trials, targeting fast-track global approvals

Featured News

Buyers (Bids)

Sellers (Offers)

Featured News

	Sales revenue $ $ $	2022	2023	2022 to 2023	2024 Projected
1		x $1000	x $1000	% change	x $1000
2					assume same %
3	Technology	$3,876.00	$4,406.00	13.67%	$5,008.47
4	Business Automation	$2,439.00	$2,148.00	-11.93%	$1,891.72
5	Acquiring	$868.00	$2,591.00	198.50%	$7,734.19
6	Alternative Payments	$17,946.00	$20,847.00	16.17%	$24,216.95
7	Banking Services - - -	$-	$-		$-
8	ATX Payments	$5,801.00	$5,564.00	-4.09%	$5,336.68
9	Issuing	$1,625.00	$3,423.00	110.65%	$7,210.42
10					$-
11		$32,555.00	$38,979.00	19.73%	$46,670.63

Ann: Annual Report to shareholders, page-19

Top Stories

Coda Minerals (ASX:COD) enters rights issue to further exploration in South Australia

SPC to merge with Original Juice Co and Nature One Dairy

Recce eyes Indonesia for novel anti-infective as Indo-Aus ties grow stronger

Cobalt Blue sees A$60M price tag for Kwinana, WA refinery – but $68M value for stage one

Actinogen Medical ramps up Alzheimer’s treatment trials, targeting fast-track global approvals

Featured News

Buyers (Bids)

Sellers (Offers)

Featured News